Tumor-Infiltrating Lymphocytes

Tumor-infiltrating lymphocytes are white blood cells of the immune system, mostly T cells, that have moved out of the bloodstream and into a tumor. Pathologists can see and count them in a tissue sample, and their number and type give clues about how actively the immune system is attacking the cancer.

Origin

Pathologists noticed long ago that some tumors are crowded with lymphocytes. Research from the 1980s onward, including work at the U.S. National Cancer Institute, showed these cells can recognize cancer, and led to a cell therapy made from a patient's own TILs, approved in the United States for advanced melanoma in 2024.

Significance in Asbestos Context

In mesothelioma, as in many cancers, research has generally linked tumors with more cytotoxic (CD8) T cells inside them to longer survival, and immune-rich tumors are thought more likely to respond to checkpoint inhibitors such as nivolumab and ipilimumab. Some studies suggest non-epithelioid (sarcomatoid and biphasic) mesotheliomas show more immune activity than epithelioid tumors, one explanation offered for why immunotherapy helped those subtypes most in the CheckMate 743 trial. Even so, TIL counts are not a routine test for deciding mesothelioma treatment: no TIL threshold is used to choose or refuse immunotherapy, and PD-L1 staining is the marker more often reported. TILs mostly appear in research papers and clinical trial reports, and TIL cell therapy for mesothelioma remains experimental. For a family, the term matters mainly when reading a pathology report, a trial consent form or a second-opinion review that discusses the tumor's immune environment.

Example Sentence

The research pathologist noted dense tumor-infiltrating lymphocytes in the biopsy, which the oncologist called an encouraging but not decisive sign for immunotherapy.

Related Terms

Tumor Microenvironment, Immunotherapy, Checkpoint Inhibitors, PD-L1, CheckMate 743, Immunohistochemistry, Pathology Report, CAR-T Cell

Notes

• TILs are usually a research finding; ask your oncologist whether they change your treatment plan.
• If you are considering a cell-therapy trial, ask what is known about results in mesothelioma specifically.
• Keep copies of any special pathology reports, including PD-L1 results.